CCM
NVO

CAAS Capital Management’s Novo Nordisk NVO Stock Holding History

CAAS Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,300
Closed -$274K – 495
2024
Q3 		$274K Buy
+2,300
New +$307K 0.03% 286

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

CAAS Capital Management's NVO Position: Q1 2025 in Review

CAAS Capital Management held its Novo Nordisk (NVO) position steady in Q1 2025 at 11,000 shares worth $764K. The position accounts for 0.08% of the portfolio, ranked #213.

CAAS Capital Management first reported a position in NVO in Q3 2024 and has held it in 3 quarters since. The position peaked at $1.26M in Q3 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • CAAS Capital Management held 11,000 shares of Novo Nordisk worth $764K as of Q1 2025.
  • CAAS Capital Management left its Novo Nordisk share count unchanged in Q1 2025.
  • Novo Nordisk made up 0.08% of CAAS Capital Management's portfolio in Q1 2025, its #213 holding.
  • CAAS Capital Management first reported a position in Novo Nordisk in Q3 2024 and has held it in 3 quarters since.
  • CAAS Capital Management's Novo Nordisk position peaked at $1.26M in Q3 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.